Malignant Thoracic Neoplasm

194 somatic mutations seen in primary lung cancers were functionally evaluated using three approaches: (1) differences in pattern or extent of changes in gene expression in A549 cells induced by trans… (full text at CIViC)

PMID 27478040 · Berger et al., 2016 · Open in CIViC

Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.

PMID 23344087 · Kim et al., 2013 · Open in CIViC

A cell line (DFCI076) with EML1-ALK fusion and resistance mutation L1152R showed no response to ALK inhibition with crizotinib or TAE684. There was co-dependancy on AKT and EGFR-signaling and inhibiti… (full text at CIViC)

PMID 21791641 · Sasaki et al., 2011 · Open in CIViC

In a PDX lung cancer model containing a heterozygous ATM F858L mutation, the MEK inhibitor selumetinib completely blocked tumor growth and induced tumor regression.

PMID 27922010 · Smida et al., 2016 · Open in CIViC

Knockdown or inactivation of ATM in KRAS-mutant (H460), KRAS- and BRAF-wildtype (H322), and BRAF-mutant (H1755) lung cancer cell lines sensitized these cell lines to trametinib.

PMID 27922010 · Smida et al., 2016 · Open in CIViC

Bi-allelic Atm deletion in mouse models of Kras-mutant lung adenocarcinoma does not affect cisplatin responses. In marked contrast, Atm-deficient tumors displayed an enhanced response to the topoisome… (full text at CIViC)

PMID 28363999 · Schmitt et al., 2017 · Open in CIViC

In this phase II basket trial (TAPUR), response to olaparib treatment was examined in four cohorts with ATM mutations. In the lung cancer cohort (20 evaluable patients) there were four PRs and five pa… (full text at CIViC)

PMID 41538762 · Carrizosa et al., 2026 · Open in CIViC

High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisp… (full text at CIViC)

PMID 25082261 · Xu et al., 2014 · Open in CIViC

In a cohort of melanoma patients treated with PD-1 antibodies, higher B2M levels were observed in those who achieved a complete response compared to those with partial response or progressive disease.… (full text at CIViC)

PMID 34115389 · Zhao et al., 2021 · Open in CIViC

The in vivo experiment demonstrated that Bap1 loss results in increased trimethylated histone H3 lysine 27 (H3K27me3), elevated Ezh2 expression, and enhanced repression of Polycomb Repressive Complex … (full text at CIViC)

PMID 26437366 · LaFave et al., 2015 · Open in CIViC

The effect of CDK4/6 inhibitors (abemaciclib or palbociclib) was tested in patient-derived malignant pleural mesothelioma (MLM) cell lines. Of the three patient-derived cell lines, two of the cell lin… (full text at CIViC)

PMID 34588615 · Aliagas et al., 2021 · Open in CIViC

A patient with lung adenocarcinoma harboring a somatic homozygous BARD1 G320* stop-gain alteration and an RBBP8 exon 3–4 duplication was classified as homologous recombination deficient by HRDetect an… (full text at CIViC)

PMID 36964191 · Tsang et al., 2023 · Open in CIViC

MPM cells transfected with BAP1Δ, an alternative splice isoform of BAP1 that misses part of the catalytic domain, showed reduced deubiquitinating activity compared with full-length BAP1. MPM cell line… (full text at CIViC)

PMID 28389374 · Parrotta et al., 2017 · Open in CIViC

The BIM (BCL2L11) deletion polymorphism was identified in an EGFR Mutant NSCLC cell line with resistance to EGFR-TKI (HCC2779). Introduction of this polymorphism in a previously EGFR-inhibitor sensiti… (full text at CIViC)

PMID 22426421 · Ng et al., 2012 · Open in CIViC

Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective anal… (full text at CIViC)

PMID 24961465 · Wu et al., 2014 · Open in CIViC

Non-V600 BRAF mutations occur frequently in NSCLC. While BRAF D594E results in impaired kinase activity, it can induce MEK/ERK activation in the presence of RAF1 (CRAF). BEAS-2B lung epithelial cell l… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

Non-V600 BRAF mutations occur frequently in NSCLC. While BRAF D594N results in impaired kinase activity, it can induce MEK/ERK activation when expressed in HEK293T cells in the presence of RAF1 (CRAF)… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC)

PMID 28783719 · Yao et al., 2017 · Open in CIViC

In the BRAF G466V-mutant NCI-H1666 model, NST-628 suppressed MAPK signaling without inducing BRAF–CRAF heterodimer formation. NCI-H1666 was also included in a panel of BRAF class II/III-mutant cell li… (full text at CIViC)

PMID 38588399 · Ryan et al., 2024 · Open in CIViC

In an in vitro study, a PC-9 cell line expressing BRAF G469A mutation demonstrated decreased sensitivity to erlotinib treatment compared to PC-9 cells expressing BRAF wild-type. Sensitivity was determ… (full text at CIViC)

PMID 22773810 · Ohashi et al., 2012 · Open in CIViC

PC9 cells harboring an in-frame deletion in exon 19 of the EGFR gene were cultured in the presence of increasing concentrations of osimertinib. Three clones resistant to osimertinib were isolated and … (full text at CIViC)

PMID 31502118 · La Monica et al., 2019 · Open in CIViC

Case report of a patient with NSCLC and BRAF G469R mutation who showed a dramatic response to sorafenib.

PMID 26237499 · Sereno et al., 2015 · Open in CIViC

Non-V600 BRAF mutations occur frequently in NSCLC. BRAF G469S increases kinase activity, as it can induce MEK/ERK activation to higher levels that wild-type BRAF when expressed in HEK293T cells. BEAS-… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

Non-V600 BRAF mutations occur frequently in NSCLC. BRAF G469V increases kinase activity, as it can induce MEK/ERK activation to higher levels that wild-type BRAF when expressed in HEK293T cells. BEAS-… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

Case report of a patient with HCC and NSCLC (only NSCLC harboring the BRAF G469V mutation). Sorafenib at standard dosage led to a partial response in the primary lesion of the lung, complete response … (full text at CIViC)

PMID 27388325 · Casadei Gardini et al., 2016 · Open in CIViC

Non-V600 BRAF mutations occur frequently in NSCLC. While BRAF G596C results in impaired kinase activity, it can induce MEK/ERK activation when expressed in HEK293T cells in the presence of RAF1 (CRAF)… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

Non-V600 BRAF mutations occur in about half of BRAF-mutated lung cancers, and their sensitivity to Dabrafenib and Trametinib is not well documented. In a cohort of 229 NSCLC patients that underwent mo… (full text at CIViC)

PMID 28947956 · Noeparast et al., 2017 · Open in CIViC

In a retrospective study of 35 lung adenocarcinoma patients (chemotherapy previously administered in 86% of patients), a patient harboring a BRAF G596V mutation was associated with partial response to… (full text at CIViC)

PMID 26200454 · Gautschi et al., 2015 · Open in CIViC

A total of 23,396 patients with lung cancer and comprehensive genomic profiling were reviewed for BRAF alterations, and kinase domain duplication (KDD) mutations were observed in 0.75% of the cases. F… (full text at CIViC)

PMID 32913992 · Sheikine et al., 2018 · Open in CIViC

Patients with BRAF-V600 mutated cancers were identified (n=122) and clinical response to vemurafenib was evaluated. Of the 20 patients with non-small-cell-lung cancer (17 with BRAF V600E, one with BRA… (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomised, open-label study, administering dabrafenib plus trametinib. The overall response rate was 36/57 … (full text at CIViC)

PMID 27283860 · Planchard et al., 2016 · Open in CIViC

In a genetic screen of 87 lung cancer cell lines, one MEK-dependent cell line HCC364 contained a BRAF-V600E mutation. In growth assays, the MEK inhibitor PD-0325901 reduced proliferation in growth ass… (full text at CIViC)

PMID 19010912 · Pratilas et al., 2008 · Open in CIViC

A 42 year old man with non-smoking history presented with EGFR L858R positive lung adenocarcinoma. He was given various treatments including erlotinib and gefitinib and progressed four years later. bi… (full text at CIViC)

PMID 29074209 · Bearz et al., 2017 · Open in CIViC

In a clinical study of 49 patients, 10 patients with Non-Small Cell Lung Cancer (NSCLC) and wild-type BRAF gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

In the lung carcinoma cohort of the phase II TAPUR trial (NCT02693535), CRs were observed in 2/25 evaluable patients, both with BRCA2 alterations, with DOR of 33 weeks (SCLC, n=1) and 148 weeks (NSCLC… (full text at CIViC)

PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC

Samples from 393 patients with NSCLC were evaluated for 3 SNPs in CBLB (rs1042852, rs2305035, and rs7649466). Genotypes rs7649466 and rs1042852 were not associated with a change in clinical outcome c… (full text at CIViC)

PMID 26732495 · Li et al., 2016 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC)

PMID 28835699 · Tan et al., 2017 · Open in CIViC

Case report of a 60-year old woman with lung adenocarcinoma. After negative testing for EGFR mutations and ALK translocations and failure of platinum-based chemotherapy she was enrolled on a nintedani… (full text at CIViC)

PMID 26787234 · Takeda et al., 2016 · Open in CIViC